MoonLake Immunotherapeutics (MLTX) - Total Liabilities
Based on the latest financial reports, MoonLake Immunotherapeutics (MLTX) has total liabilities worth $146.35 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MoonLake Immunotherapeutics asset resilience ratio to evaluate the company's liquid asset resilience ratio.
MoonLake Immunotherapeutics - Total Liabilities Trend (2020–2025)
This chart illustrates how MoonLake Immunotherapeutics's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of MoonLake Immunotherapeutics.
MoonLake Immunotherapeutics Competitors by Total Liabilities
The table below lists competitors of MoonLake Immunotherapeutics ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
STEVANATO GROUP SPA O.N.
F:87N
|
Germany | €1.07 Billion |
|
eXp World Holdings Inc
NASDAQ:EXPI
|
USA | $223.48 Million |
|
Shandong Head Co Ltd
SHE:002810
|
China | CN¥1.77 Billion |
|
Supply Network Ltd
AU:SNL
|
Australia | AU$102.56 Million |
|
Dorian LPG Ltd
NYSE:LPG
|
USA | $713.63 Million |
|
Episil-Precision Inc
TW:3016
|
Taiwan | NT$1.83 Billion |
|
Blue Square Real Estate Ltd
TA:BLSR
|
Israel | ILA8.21 Billion |
|
I.E.S Holdings Ltd
TA:IES
|
Israel | ILA367.96 Million |
Liability Composition Analysis (2020–2025)
This chart breaks down MoonLake Immunotherapeutics's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See MoonLake Immunotherapeutics balance sheet independence to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.58 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how MoonLake Immunotherapeutics's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for MoonLake Immunotherapeutics (2020–2025)
The table below shows the annual total liabilities of MoonLake Immunotherapeutics from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $119.95 Million | +388.76% |
| 2024-12-31 | $24.54 Million | +88.08% |
| 2023-12-31 | $13.05 Million | +61.57% |
| 2022-12-31 | $8.08 Million | -62.13% |
| 2021-12-31 | $21.33 Million | +413.89% |
| 2020-12-31 | $4.15 Million | -- |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more